| 摘要 |
A method for correcting carbohydrate metabolism and decreasing the body mass in metabolic syndrome (MS) provides for examining the patients, diagnosing MS and administering the drugs that normalize carbohydrate metabolism. MS is diagnosed according to the criteria of the International Diabetes Federation (IDF, 2005) as modified in 2009 by the American Heart Association (AHA) and National Heart, Lung and Blood Institute (NHLBI). The patients with MS and impaired carbohydrate metabolism (fasting glycemia ≥ or 100 mg/dL) or previously diagnosed diabetes mellitus type 2 and/or abdominal obesity (waistline ≥ in males and ≥ in females), the inhibitors of sodium-glucose cotransporter-2 (Dapagliflozin, Canaglyflozin) are prescribed once a day at a dose of 10-20 mg on an individual basis. |
